EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Potential of Selected C-X-C Motif Chemokines as Biomarkers in Colorectal Cancer Diagnosis

Adrianna Romanowicz, Marta Łukaszewicz-Zając iD, Barbara Mroczko iD

International Journal of Molecular Sciences · 07.09.2025 · 26 (17) · 8715

DOI: 10.3390/ijms26178715 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.09.2025. Verfasst von Adrianna Romanowicz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Biomarkers, Tumor, Chemokines, CXC, Chemokines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: medical university of bialystok.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide, mainly due to late diagnosis and high metastatic potential. Effective management requires accurate diagnostic, prognostic, and therapeutic strategies, with growing focus on molecular biomarkers. Chemokines, which are small, secreted proteins regulating immune cell migration and tissue homeostasis, shape the tumor microenvironment by promoting tumor growth, angiogenesis, immune evasion, and metastasis. In CRC, the expression of altered chemokine–receptor profiles correlates with progression and clinical outcomes. Chemokines are classified by the presence or absence of the ELR motif, which differentiates CXC subgroups. Selection focused on those consistently altered in CRC tissues or serum and involved in key oncogenic processes. CXCL1 and its receptor CXCR2 are overexpressed and linked to tumor progression, highlighting their diagnostic and therapeutic potential. CXCL8 is elevated in tissues and serum, correlating with metastasis and poor survival. The CXCL12/CXCR4/CXCR7 axis drives metastasis. CXCL13 promotes immune evasion via CXCR5, while CXCL14 is downregulated, suggesting a protective role. Moreover, CXCL16 associates with worse outcomes, whereas CXCR6 may enhance immunotherapy response. Overall, chemokines and receptors are promising blood biomarkers and therapeutic targets in CRC. Further validation is needed using large prospective studies, standardized assays, and multi-marker approaches to establish their potential as non-invasive CRC biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBiomarkers, TumorChemokines, CXCChemokinesHumansTumor MicroenvironmentPrognosis

Stichwörter der Autor:innen

biomarkerchemokinescolorectal cancer

Substanzen

Biomarkers, TumorChemokines, CXCChemokines

Autor:innen und Institutionen

  • Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.
  • Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.

ORCID-Profile: Marta Łukaszewicz-Zając, Barbara Mroczko

Förderung

  • medical university of bialystok

Zitieren

APA

Romanowicz, A., Łukaszewicz-Zając, M., & Mroczko, B. (2025). Potential of Selected C-X-C Motif Chemokines as Biomarkers in Colorectal Cancer Diagnosis. International Journal of Molecular Sciences, 26(17), 8715. https://doi.org/10.3390/ijms26178715

Vancouver

Romanowicz A, Łukaszewicz-Zając M, Mroczko B. Potential of Selected C-X-C Motif Chemokines as Biomarkers in Colorectal Cancer Diagnosis. International Journal of Molecular Sciences. 2025;26(17):8715. doi:10.3390/ijms26178715

BibTeX
@article{Romanowicz2025,
  author = {Romanowicz, Adrianna and Łukaszewicz-Zając, Marta and Mroczko, Barbara},
  title = {Potential of Selected C-X-C Motif Chemokines as Biomarkers in Colorectal Cancer Diagnosis},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {17},
  pages = {8715},
  doi = {10.3390/ijms26178715}
}
Kostenlos starten →